Windtree Therapeutics, Inc. Graham Net Nets

Graham Net Nets of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Graham Net Nets growth rates and interactive chart. Net current asset value divided by market cap. Calculated as current assets minus total liabilities divided by market cap.


Highlights and Quick Summary

Current Graham Net Nets of Windtree Therapeutics, Inc. is -0.14 (as of December 30, 2019)
  • Graham Net Nets for the quarter ending December 30, 2019 was -0.14 (a -42.2% decrease compared to previous quarter)
  • Year-over-year quarterly Graham Net Nets decreased by -87.31%
  • Annual Graham Net Nets for 2019 was -0.14 (a -87.31% decrease from previous year)
  • Annual Graham Net Nets for 2018 was -1.14 (a -76.15% decrease from previous year)
  • Annual Graham Net Nets for 2017 was -4.78 (a 61.38% increase from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Graham Net Nets of Windtree Therapeutics, Inc.

Most recent Graham Net Netsof WINT including historical data for past 10 years.

Interactive Chart of Graham Net Nets of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Graham Net Nets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -0.14 -0.25 -0.24 -0.14
2018 -1.14 -2.85 -1.95 -2.9 -1.14
2017 -4.78 -13.38 -10.18 -2.73 -4.78
2016 -2.96 -1.2 -1.15 -0.61 -2.96
2015 0.23 0.44 -0.08 0.06 0.23
2014 0.17 0.17 0.24 0.25 0.17
2013 0.45 0.03 0.19 0.07 0.45
2012 0.19
2011 0.11 0.39 -0.04

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.